[{"NetIncomeLoss_1_Q2_USD":-46426000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":73237.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q2_USD":83770000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":45979000.0,"InventoryFinishedGoods_0_Q2_USD":302000.0,"OperatingCostsAndExpenses_2_Q2_USD":1215000.0,"OperatingCostsAndExpenses_1_Q2_USD":396000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":891000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":714000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-106513000.0,"StockIssuedDuringPeriodValueNewIssues_2_Q2_USD":161802000.0,"AssetsCurrent_0_Q2_USD":317836000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":205773000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":70475.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":61521000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":5072000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":2339000.0,"AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_0_Q2_Security":34.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":99286000.0,"CommonStockSharesIssued_0_Q2_shares":73366000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":242471000.0,"Assets_0_Q2_USD":380011000.0,"ShareBasedCompensation_2_Q2_USD":11580000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":10013000.0,"DeferredRevenue_0_Q2_USD":297000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":30843000.0,"DepreciationAndAmortization_2_Q2_USD":480000.0,"ConvertibleLongTermNotesPayable_0_Q2_USD":113776000.0,"EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_0_Q2_USD":2300000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":76591000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":42594000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0_Q2_USD":43000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-32000.0,"AssetsFairValueDisclosure_0_Q2_USD":298276000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-36000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-61000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":203000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":137000.0,"CommonStockValue_0_Q2_USD":7000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q2_USD":48856000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":43000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":166875000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q2_USD":43000.0,"IncreaseDecreaseInInventories_2_Q2_USD":1306000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-98429000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-45115000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":903000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":103102000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":12278000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":1101596000.0,"Liabilities_0_Q2_USD":250212000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":5072000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":1273000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":959000.0,"AvailableForSaleSecuritiesAmortizedCost_0_Q2_USD":241518000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"ConvertibleDebtFairValueDisclosures_0_Q2_USD":104700000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":682000.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":51652000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-972695000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-24958000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":1719000.0,"ProceedsFromConvertibleDebt_2_Q2_USD":172500000.0,"CommonStockSharesOutstanding_0_Q2_shares":73366000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-99154000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-46289000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":6428000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":11580000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":38000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":-31000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-85288000.0,"LiabilitiesCurrent_0_Q2_USD":50570000.0,"DeferredRevenueCurrent_0_Q2_USD":297000.0,"AccountsPayableCurrent_0_Q2_USD":1888000.0,"NonoperatingIncomeExpense_2_Q2_USD":-11479000.0,"NonoperatingIncomeExpense_1_Q2_USD":-5970000.0,"InterestExpense_2_Q2_USD":13267000.0,"InterestExpense_1_Q2_USD":6758000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":105731000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":7971000.0,"PaymentsForRoyalties_2_Q2_USD":2400000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q2_USD":83770000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"ReceivablesNetCurrent_0_Q2_USD":9581000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":2592000.0,"NetIncomeLoss_2_Q2_USD":-99357000.0,"AmortizationOfFinancingCostsAndDiscounts_2_Q2_USD":3919000.0,"DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0_Q2_USD":67900000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-89000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":26000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":33514000.0,"DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2_Q2_D":5.0,"OperatingIncomeLoss_2_Q2_USD":-87675000.0,"OperatingIncomeLoss_1_Q2_USD":-40319000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":193615000.0,"InventoryNet_0_Q2_USD":1652000.0,"DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_2_Q2_USD":0.0,"InvestmentIncomeInterest_2_Q2_USD":1824000.0,"InvestmentIncomeInterest_1_Q2_USD":849000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":996000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":380011000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"InventoryWorkInProcessAndRawMaterialsNetOfReserves_0_Q2_USD":1350000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":11580000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":6428000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1778000.0,"OperatingExpenses_2_Q2_USD":139327000.0,"OperatingExpenses_1_Q2_USD":73833000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":5228000.0,"RestrictedCashAndCashEquivalentsAtCarryingValue_0_Q2_USD":1915000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.41,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.63,"ProfitLoss_2_Q2_USD":-99357000.0,"AllowanceForDoubtfulAccountsReceivableWriteOffs_2_Q2_USD":0.0,"OtherLiabilitiesCurrent_0_Q2_USD":628000.0,"StockholdersEquity_0_Q2_USD":129799000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q2_USD":0.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-4236000.0,"Ticker":"KPTI","CIK":"1503802","name":"KARYOPHARM THERAPEUTICS INC.","OfficialName":"Karyopharm Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"566245834.0","Country":"United States","Sector":"Miscellaneous","Industry":"Diversified Commercial Services","Market":"NASDAQ","SP500":"nan","filed":"20200804"}]